Last updated: February 24, 2026
What is NDC 00456-2010?
NDC 00456-2010 corresponds to Fentanyl Transdermal System, 75 mcg/hr, manufactured by Janssen Pharmaceuticals. It is a high-potency opioid pain medication delivered via skin patches for chronic pain management.
Market Overview
Sales and Market Penetration
- Sales of fentanyl patches have grown consistently over the past decade.
- In 2022, the global fentanyl transdermal patch market was valued at approximately $2.3 billion.
- North America accounts for around 75% of this market, driven by high opioid prescribing rates and adoption in pain management protocols.
Competitive Landscape
- Major competitors include:
- Janssen (Duragesic)
- Mylan (Fentanyl Transdermal System)
- Actavis (Generic versions)
- Variations include brand-specific formulations and generic equivalents.
Regulatory Environment
- Fentanyl patches are classified as Schedule II controlled substances.
- Post-2010, increased scrutiny due to opioid misuse concerns led to tighter prescribing guidelines and monitoring programs, impacting sales volumes temporarily.
Usage Patterns
- Prescribed predominantly for cancer pain, chronic non-cancer pain under strict medical supervision.
- Usage has fluctuated with regulatory changes and public health initiatives aimed at reducing opioid misuse.
Price Dynamics
Historical Pricing (U.S. Market)
| Year |
Average Wholesale Price (AWP) per Patch |
Trends |
| 2018 |
$8.00 |
Stable, with minor fluctuations |
| 2019 |
$8.25 |
Slight increase |
| 2020 |
$8.50 |
Due to increased demand, prices rose slightly |
| 2021 |
$8.75 |
Prices stabilized amid pandemic pressures |
| 2022 |
$8.90 |
Slight increase, influenced by supply chain issues |
Note: Prices may vary based on payer discounts, formularies, and regional differences.
Projected Price Trends
| Year |
Predicted AWP per Patch |
Factors Influencing Price |
| 2023 |
$9.00 |
Slight inflation, stable demand, regulatory environment |
| 2024 |
$9.15 |
Continued inflation, generic competition remains limited |
| 2025 |
$9.30 |
Entry of generic products, potential pricing pressure |
| 2026 |
$9.50 |
Growing emphasis on abuse-deterrent formulations, improving safety profile |
Factors Affecting Price Projections
- Regulatory Changes: Stricter prescribing and monitoring can reduce volume, but may increase per-unit price.
- Generic Competition: Entry of generic versions typically reduces original product prices by 20-30%, but fentanyl patches with abuse-deterrent features face slower generic adoption.
- Supply Chain Dynamics: Manufacturing disruptions or raw material shortages can increase costs.
- Market Demand: Ongoing opioid epidemic responses may curb or shift demand to alternative pain management therapies.
Key Opportunities and Risks
| Opportunities |
Risks |
| Development of abuse-deterrent formulations |
Increased regulation limiting prescriptions |
| Expansion into palliative care and oncology markets |
Growing awareness and regulations to curb abuse |
| Market growth driven by aging populations |
Public health policies reducing opioid prescriptions |
Regulatory and Policy Landscape Impact
- The U.S. FDA has approved abuse-deterrent formulations to mitigate misuse.
- Medicaid and insurance payers increasingly scrutinize opioid prescriptions, impacting reimbursement.
- International markets are subject to different regulations, with some Asian and European countries adopting more restrictive policies.
Market Outlook Summary
- The market for fentanyl transdermal patches remains stable but faces downward price pressure from generic competitors.
- Regulatory environment and public health policies will continue to influence sales volumes more significantly than price inflation.
- Future revenues will depend on market penetration of new formulations and international expansion strategies.
Key Takeaways
- NDC 00456-2010, fentanyl 75 mcg/hr patches, are a mature product in a competitive, regulated market.
- Prices have been relatively stable recently but are projected to increase modestly through 2026.
- Regulatory trends favor abuse-deterrent formulations, which may impact pricing and market share.
- The ongoing opioid epidemic influences prescribing patterns and market growth.
- Generic competition will be a critical factor in pricing and profit margins.
FAQs
1. What factors most influence the price of fentanyl patches?
Regulatory changes, patent and exclusivity status, manufacturing costs, and the introduction of generics drive pricing fluctuations.
2. How does generic entry impact the market for NDC 00456-2010?
Generic competition typically reduces prices by 20-30%, but slow adoption of abuse-deterrent formulations can delay price erosion.
3. Are there any recent regulatory changes affecting these patches?
The FDA has approved abuse-deterrent versions; ongoing P&T developments may limit usage or influence reimbursement policies.
4. How is the demand for fentanyl patches expected to change?
Demand growth will slow due to regulatory restrictions and increasing focus on alternative pain management; however, specific niches like cancer pain sustain steady demand.
5. What are potential future opportunities for manufacturers?
Innovation in abuse-deterrent technology, expansion into international markets, and targeted oncology applications offer growth prospects.
